ALK-B vs NOVO-B: Side-by-Side Comparison
Compare ALK-Abelló A/S (ALK-B) and Novo Nordisk A/S (NOVO-B) side by side: market cap DKK 54.11B vs DKK 1.39T, P/E 42.0 vs 11.5. Financials, growth and model signals on Bullrun.
| Metric | ALK-B | NOVO-B |
|---|---|---|
| Company | ALK-Abelló A/S | Novo Nordisk A/S |
| Country / Exchange | Denmark · CO | Denmark · CO |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Drug Manufacturers - General |
| Market cap | DKK 54.11B | DKK 1.39T |
| P/E ratio | 42.0 | 11.5 |
| Dividend yield | 0.66% | 5.00% |
| Valuation model | 6.2% overvalued | 21.7% undervalued |
| Revenue (FY2025) | DKK 6.31B | DKK 309.06B |
| Revenue growth YoY | +14.0% | +6.4% |
| Net income | DKK 1.20B | DKK 102.43B |
| Gross margin | 67.1% | 81.0% |
| Diluted EPS | 540.00 | 23.03 |